In general, the percentage of complete remissions is 85 - 90 % for acute lymphoid leukemia (ALL). In developing countries, percentages are lower secondary to higher sepsis-related mortality. Although the effect of statins on inflammatory response associated with sepsis has been demonstrated, including an effect on bacterial proliferation in patients with a state of immunosuppression, their effect has not been demonstrated so far in patients with hemato-oncological cancer.

Death associated with sepsis is one of the principal complications related to chemotherapy treatment; there are currently no strategies to prevent its development besides the use of prophylactic antibiotics or granulocyte colony stimulants to reduce the period of febrile neutropenia. Most of the trials on the use of statins are retrospective with controversial results and include patients with different clinical situations that conditioned the septic study.

Inclusion Criteria:

• Patients diagnosed with acute leukemia under treatment of a chemotherapy regimen
• Stable performance status (ECOG: 0 or Karnofsky scale greater than 80%) at time of analysis and under chemotherapy regimen
• Life expectancy greater than 48 hours after diagnosis
• Oral route available
• Have signed informed consent at the time of the study
• Patients whose chemotherapy regimen is administered in a hospital rather than an outpatient manner

Exclusion Criteria:

• Patients with acute leukemias over 55 years of age and with impaired functional status at the time of diagnosis
• Elevation of liver enzymes 3 times higher than the range established by the central laboratory
• Persistent kidney involvement despite having adequate hydration
• Pregnant patients
• Patients with peripheral neuropathy considered severe or disabling grade
• Patients with a history of psychiatric disorders or psychotic attacks
• Individuals who do not have the oral route available, who are maintained with a nasogastric tube, or who require support for the diagnosis through parenteral nutrition
• Patients undergoing peritoneal dialysis or hemodialysis treatment
• Patients with leukemia associated with Down syndrome
• Patients under low-intensity chemotherapy regimen or palliative regimen
• Previous allergy to any statin component
• Patients with a history of liver failure (Child-Pugh Stage B or C)

All participants and their information will be managed by intern investigators and will be kept secure for personal data protection according to Mexican laws.